端粒酶逆转录酶
生物
细胞培养
端粒酶
分子生物学
异位表达
转录组
细胞生物学
基因表达
基因
遗传学
作者
Chaohu Wang,Huarong Zhang,Rongrong Guo,Yanan Cao,Jun Pan,Haoying Yu,Xiaoyu Qiu,Shi Jin,Jun Fan,Songtao Qi,Yi Liu
摘要
Abstract Aims Adamantinomatous craniopharyngioma (ACP) is a rare benign intracranial tumour that occurs in the sellar region and likely originates from the embryonic craniopharyngeal epithelium (a remnant of the ectoderm, also known as Rathke's pouch). However, progress in ACP research has been slow due to the lack of ACP cell lines. Therefore, in this study, we established an immortalised ACP cell line. Methods Immortalised ACP cells were established from cultured primary ACP cells by the ectopic expression of human telomerase reverse transcriptase ( hTERT ). Primary and immortalised cells were compared and characterised by morphological examination, short tandem repeat (STR) profiling, whole exome sequencing (WES) and transcriptome sequencing. The ability of immortalised cells to form tumours was examined using an intracranial tumour formation assay in mice. Immunofluorescence staining was performed to compare the characteristics of human ACP and intracranial xenografts derived from immortalised cells. Results A novel immortalised ACP cell line, STAM4, was successfully established in a 4‐year‐old male ACP patient. When STAM4 cells were compared with primary ACP cells in terms of morphological characteristics, genetic variants, STR profiles, biological behaviours and transcriptome differences, STAM4 cells were similar to primary ACP cells. Additionally, the STAM4 cells were able to form intracranial tumours that resemble human ACP. Conclusions This ACP cell line may provide a cell model for further studies on the molecular mechanisms underlying the occurrence and progression of ACP and for the development of new anticancer drugs for ACP.
科研通智能强力驱动
Strongly Powered by AbleSci AI